Bone Health Technologies (BHT) has announced the appointment of Dr. Pamela Peeke as Chief Medical Officer and board member. Furthermore, Dr. Kian Beyzavi and Marcie Hamilton have been appointed as new board directors. The addition of these skilled professionals will bolster BHT’s product, research, and commercial growth, solidifying its position as the standard of care for osteoporosis and osteopenia treatment.
Dr. Peeke, a clinical scientist with expertise in women’s health, menopause, and longevity, will be a valuable addition to the team. As an Assistant Professor of Medicine at the University of Maryland, she holds prominent positions on the National Menopause Foundation Medical Advisory Board and the American College of Sports Medicine Board. BHT CEO Laura Yecies expressed her excitement for Dr. Peeke’s involvement, emphasizing her role in achieving the company’s vision of a safe, non-pharmacological, clinically-proven solution for individuals with low bone density.
Joining BHT’s board are Dr. Kian Beyzavi and Marcie Hamilton, both bringing valuable experience to the company. Dr. Beyzavi earned her PhD in Electrical Engineering/Applied Physics from Princeton University and has played an instrumental role in the development of numerous MedTech, Digital Health, and Biopharma products across 60 companies. Her work revolves around harnessing dynamic data, AI, and machine learning to advance patient care and provide a holistic view of the healthcare landscape. Marcie Hamilton, on the other hand, offers her expertise in medical devices and consumer products, having earned her B.S. in Mechanical Engineering from Purdue University and co-founding Potrero Medical.
The appointment of these professionals demonstrates BHT’s commitment to advancing the treatment of osteoporosis and osteopenia. CEO Laura Yecies highlighted their importance in bolstering the medical and commercial organization, stating, “Dr. Peeke’s expertise in and approach to longevity and women’s health aligns with our vision for a safe, non-pharmacological, clinically-proven solution for the tens of millions with low bone density. We are excited to have her on board. Moreover, Dr. Beyzavi and Ms. Hamilton bring extensive medical device development and commercialization experience to BHT.”